PCRX

Pacira Biosciences Stock Analysis

AI Rating

Low
  • Quality5/10
  • Growth 0/10
  • Value 3/10
Pacira Biosciences sales and earnings growth
PCRX Growth
Low
  • Revenue Y/Y 12.48%
  • EPS Y/Y 105.33%
  • FCF Y/Y -16.75%
Pacira Biosciences gross and profit margin trends
PCRX Profitability
Neutral
  • Gross margin 79.30%
  • EPS margin 0.70%
  • ROIC 5Y 1.82%
Pacira Biosciences net debt vs free cash flow
PCRX Risk
Great
  • Debt / Equity 0.6
  • Debt / FCF 2.0
  • Interest coverage 1.8

Pacira Biosciences stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Drug Manufacturers - Specialty & Generic stocks